

Medidata Rave Imaging Reaches Milestone, Supporting More Than 1,000 Clinical Studies

A Rapidly Growing Trend, More than 50% of Clinical Trials Now Involve Medical Imaging

New York — October 12, 2021 — Medidata, a Dassault Systèmes company, today announced that <u>Rave Imaging</u>, the company's cloud-based, secure clinical trial imaging management platform, has reached a significant milestone, having supported more than 1,000 imaging studies. Rave Imaging, built on the <u>Medidata Unified Platform</u>, processes more than 100 million images annually. The technology provides unprecedented real-time visibility into all imaging-related trial activities across all Rave Imaging trials to enhance study efficiency.

With more than 50% of clinical trials involving medical imaging, sponsors require a trusted, secure, and integrated technology to manage the increasing amount and complexity of imaging data.*

"Medidata continues to be an outstanding partner for ICON Medical Imaging. Our close relationship over the years has resulted not only in reduced timelines and increased value with our sponsors but also improved ease of use and decreased administrative burden for sites," said Paul J. McCracken, Ph.D., vice president, head of medical imaging (IMI), ICON Clinical Research. "We've leveraged Rave Imaging on many studies because of our confidence in the technology's reliability, flexibility, and continued innovation (such as in machine learning) to help us successfully deliver all types of current and anticipated imaging trial needs."

Rave Imaging's structured approach to image submission reduces the time and cost associated with image management, while increasing data quality and confidence. The technology provides:

- Unified site experience with a single solution for all sites across all Rave Imaging trials and Core Labs
- Flexibility to select and integrate with any Core Labs, system, or vendor
- Standardized image submission processes including acquisition, de-identification, edit checks, distribution, review, and archiving across all trials and Core Labs
- Data security adherent to privacy and information management guidelines

"Medidata's Rave Imaging system has powered many of our key studies over the past eight years. Medidata continues to innovate and invest in their imaging technology, giving us the robust functionality we need to run efficient trials with the quality we trust," said Blessie

Concepcion, director, Global Clinical Trials at Boston Scientific. "Medical Imaging is a critical component of many of our trials. It's essential to have a technology partner like Medidata that will bring the expertise, experience, and service to help us get our devices to market faster."

Integration with the other components of Medidata Unified Platform uniquely positions Rave Imaging to serve as an essential tool that can be used to collect imaging outcomes and then automatically correlate them with clinical outcomes. In addition, Medidata continues to invest in Rave Imaging, with a particular focus on artificial intelligence algorithms -- such as automatic lesion detection and automatic anatomical verification -- that can increase the efficiency of trials, while addressing cost and efficiency challenges, and improving data quality.

"This is a wonderful milestone to celebrate with our outstanding team and pioneering clients," said Dr. Rama Kondru, co-CEO, Medidata. "With the flurry of M&A activity in the imaging technology and core lab space, it will be critical for sponsors to optimize their medical image management strategy with a trusted, experienced, enterprise partner. Medidata is ideally suited to be the partner of choice, with studies across 21,000 sites connected with over 75 Core Labs and contract research organizations (CROs)."

Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.

*https://brackendata.com/blog-posts/medical-imaging-clinical-trials-growth-rate

About Medidata

Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 1,700+ customers and partners access the world's most trusted platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systèmes company (Euronext Paris: FR0014003TT8, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com and follow us <u>@Medidata</u>.

About Dassault Systèmes

Dassault Systèmes, the 3DEXPERIENCE Company, is a catalyst for human progress. We provide business and people with collaborative 3D virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers push the boundaries of innovation, learning and production. Dassault Systèmes brings value to more than 290,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit <u>www.3ds.com</u>.

3DEXPERIENCE, the Compass icon, the 3DS logo, CATIA, BIOVIA, GEOVIA, SOLIDWORKS, 3DVIA, ENOVIA, NETVIBES, MEDIDATA, CENTRIC PLM, 3DEXCITE, SIMULIA, DELMIA, and IFWE are commercial trademarks or registered trademarks of Dassault Systèmes, a French "société européenne" (Versailles Commercial Register # B 322 306 440), or its subsidiaries in the United States and/or other countries.

Contact

Thomas Paolella Senior Director, Corporate Communications & Affairs +1-848-203-7596 tpaolella@medidata.com

Paul Oestreicher External Communications Director +1-917-522-4692 poestreicher@medidata.com